MedStory: The Hidden Gene Behind Sudden Cardiac Death

Why It Matters

A viable gene therapy for PKP2‑related ARVC transforms a fatal, undiagnosed condition into a treatable disease, enabling early detection and preventing sudden cardiac deaths among athletes and their families.

Key Takeaways

• Arrhythmogenic cardiomyopathy linked to PKP2 gene mutations in patients
• Stanford's HEROIC PKP2 trial tests viral gene therapy for PKP2
• Therapy delivers functional PKP2 via non‑replicating viral capsid
• Early results show safety and improved right‑ventricular function
• Precision diagnosis could expand treatment to at‑risk families worldwide

Summary

The video explains how a rare inherited disorder, arrhythmogenic right‑ventricular cardiomyopathy (ARVC), is driven by mutations in the plakophilin‑2 (PKP2) gene, a hidden cause of sudden cardiac death in young athletes.

Stanford’s HEROIC PKP2 trial uses a non‑replicating adeno‑associated virus to deliver a functional copy of PKP2 directly to heart cells, aiming to restore intercellular connections, halt fatty‑scar replacement, and reduce life‑threatening arrhythmias. Early safety data are reassuring and suggest modest improvements in right‑ventricular ejection fraction.

As one researcher notes, “If we can replace the broken gene, we can repair the heart and prevent deterioration.” The approach leverages a viral capsid as a precise delivery vehicle, a technical hurdle previously limiting cardiac gene therapy.

Successful implementation would turn a previously untreatable genetic diagnosis into a targeted therapy, prompting wider genetic screening and offering families a concrete preventive option, potentially saving countless lives.

Original Description

They collapse without warning, on a track, on a field, mid-stride. Young athletes in peak condition, gone in an instant. For many families, the cause is a devastating discovery: a hidden genetic disease passed silently across generations.

In this episode of MedStory, Stanford Department of Medicine cardiologist Dr. Victoria Parikh explores arrhythmogenic cardiomyopathy (ACM) — a rare inherited condition that disrupts the heart’s structure and rhythm, often leading to sudden cardiac death.

For decades, treatment has focused on managing risk. Now, a new frontier is emerging: gene therapy.

This video takes you inside the first-in-human HEROIC-PKP2 clinical trial, where researchers are testing an experimental therapy (LX2020) designed to correct the underlying genetic defect. Early findings offer cautious optimism, not just for stabilizing disease, but for fundamentally changing how it’s treated.